Recently, Liu et al. identified two mutated genes, NUP214 and JAK1, as biomarkers for recognition of ovarian cancers by genomics and bioinformatics approaches and introduced a novel strategy to screen the neoantigens in the ovarian cancer tissue, with a validation rate of 19%, which was far higher than that of the traditional method (35). This evidence concerns the gene NUP214 and ovarian carcinoma.